Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for HIV-associated (AIDS-related) lymphomas, drawn from the whole corpus: 2 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Primary effusion lymphoma and multicentric Castleman disease respond poorly to chemotherapy; pomalidomide, anti-IL-6 and HHV-8-directed approaches are in AMC trials.
Plasmablastic lymphoma lacks CD20 and relapses early; bortezomib and daratumumab combinations are being tested.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
CNS lymphoma at low CD4 counts remains hard to cure; high-dose methotrexate with antiretroviral therapy is now the approach rather than radiotherapy alone.
Most HIV-associated lymphoma now occurs in sub-Saharan Africa with limited access to rituximab, pathology and supportive care; global oncology programmes are the response.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · Funding verdicts by country.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 11 changes by month →When this page itself was last checked or edited.
Case series and the AMC-sponsored study show safety; trial eligibility broadened.
Kaposi sarcoma (AIDS-related after ART failure; HIV-negative)
Outcomes comparable to HIV-negative controls.
One-year overall survival 87.
R-CHOP or dose-adjusted EPOCH-R at full dose with concurrent antiretroviral therapy (avoiding boosted protease inhibitors or cobicistat where possible), G-CSF support and opportunistic-infection prophylaxis; CNS prophylaxis by risk. (NCCN Category 2A)